A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants

Overview of attention for article published in Retrovirology, December 2012

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

patent: 27 patents

Readers on

mendeley: 34 Mendeley

So far, Altmetric has seen 27 patents that reference this research output.

Substituted quinazolines for inhibiting kinase activity

Grant US-12403145-B2

United States of America

02 Sep 2025

Certain chemical entities, compositions, and methods

Grant US-12018002-B2

United States of America

25 Jun 2024

Substituted quinazolines for inhibiting kinase activity

Grant US-11865120-B2

United States of America

09 Jan 2024

Certain chemical entities, compositions, and methods

Grant AU-2020210312-B2

Australia

20 Oct 2022

This page shows the most recent patents that mention this research output. Click here to find out how to access more activity, including 23 additional patents.